"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

As symptoms progress, complications may occur, particularly in infants, who can be subject to pneumonia, heart failure, collapsed lung, brain bleeds and even death. In older children and adults, ...

Meeting, held April 24–28 in Honolulu, reveals that young children with chronic conditions are more likely to be hospitalized ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study. The research will be presented at ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

The Department of Health has announced that the jab would be more widely available as part of a wider package of preventative ...

Lung health is a cornerstone of overall wellness, influencing everything from energy levels to immunity. With rising concerns about respiratory illnesses and the aftermath of the COVID-19 pandemic ...